Table 2.
Comparison of the clinical manifestations of patients in various gB genotype groups
| CMV gB genotype 1 | CMV gB genotype 3 | P value | |||
| Mean±SD | Range, median | Mean±SD | Range, median | ||
| N (%) | 11, 78.6% | 3, 21.4% | |||
| Male (n, %) | 10, 90.9% | 2, 66.7% | 0.396 | ||
| Age at the clinic visit (years) | 41.55±11.25 | 28–62, 40 | 52.33±14.19 | 37–65, 55 | |
| Age at the first onset (years) | 37±12 | 22–56, 34 | 47±17 | 31–64, 45 | |
| Course of disease (years) | 4.7±2.8 | 1–10, 4 | 5.7±4.5 | 1–10, 6 | |
| Bilateral (n, %) | 1, 9.1% | 2, 66.7% | 0.093 | ||
| Frequency of onset (n/year) | 1.5±0.8 | 1–3, 1 | 1.7±0.6 | 1–2, 2 | 0.209 |
| GC dependence (n, %) | 7, 63.6% | 1, 33.3% | 0.538 | ||
| Anti-HCMV IgG (s/co) | 0.94±0.79 | 0.24–2.39, 0.67 | 0.67±0.71 | 0.24–1.49, 0.27 | |
| Response to antiviral therapy (n of Cc, %) | 5, 45.5% | 1, 33.3% | 1.000 | ||
| VA (LogMAR) | 0.36±0.48 | 0.00–1.70, 0.22 | 0.23±0.32 | 0.00–0.6, 0.10 | |
| Ratio of C/D | 0.59±0.22 | 0.3–0.9, 0.5 | 0.47±0.12 | 0.4–0.6, 0.4 | |
| Peak IOP | 48±5 | 41–60, 48 | 48±3.5 | 45–52, 48 | |
| Corneal endothelial cell loss (%) | 0.14±0.09 | −0.03–0.27, 0.12 | 0.08±0.09 | −0.02–0.14, 0.12 | |
| KPs (n, %) | |||||
| Sheep-fat | 10, 90.9% | 2, 66.7% | 0.396 | ||
| Coin-shaped | 5, 45.5% | 3, 100% | 0.209 | ||
| Pigmented | 1, 9.1% | 2, 66.7% | 0.093 | ||
| Tyndall effect (n, %) | 3, 27.3% | 2, 66.7% | 0.505 | ||
| Iris depigmentation (n, %) | 8. 72.3% | 3, 100% | 1.000 | ||
| Cataract (n, %) | 4, 36.4% | 2, 66.7% | 0.583 | ||
| Glaucomatous optic neuropathy (n, %) | 8, 72.3% | 1, 33.3% | 0.505 | ||
Statistical analysis was performed using Fisher’s exact test.
C/D, cup to disk ratio; gB, glycoprotein B; GC, glucocorticoid; HCMV, human cytomegalovirus; IgG, immunoglobulin G; IOP, intraocular pressure; KPs, keratic precipitates; LogMAR, logarithm of mininal angle resolution; n of Cc, number of patients with the 'complete control' outcome; VA, visual acuity.